Asthma
Conditions
Keywords
mobile Health, mHealth, Propeller Health, MF/IND/GLY Breezhaler®, FDC, Fixed dose combination, Mometasone Fuorat, Indacaterol, Glycopyrronium
Brief summary
This study is designed as a multicenter, observational, non-interventional, open label, 26-week study in order to observe how asthma control changes under treatment with Mometasone Fuorat/Indacaterol/ Glycopyrronium (MF/IND/GLY) Breezhaler® sensor system or under treatment with fixed-dose combination (FDC) triple therapy after 26 weeks of treatment.
Detailed description
Subjects in one group will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® and access to the smartphone app according to label. Subjects in the other group will receive any triple FDC according to label. The physician's decision to initiate or switch a patient to MF/IND/GLY Breezhaler® system or any other triple FDC must have been taken prior to and independently from the decision to include the patient in the study.
Interventions
COMBINATION_PRODUCTMF/IND/GLY plus sensor system
There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled. Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label.
DRUGFDC therapy
There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
To participate in the study, all of the following inclusion criteria must be met: 1. Patients (m/f/d) at the age of ≥18 2. Written declaration of consent 3. Asthma diagnosis according to German Asthma Guideline NVL, 4th edition 4. Suitability for a therapy with MF/IND/GLY in combination with the sensor system or another ICS+LABA+LAMA FDC according to SPC 5. At least 6 months of inhaled therapy with ICS+LABA (high dose) or ICS+LABA+LAMA (medium or high dose) before switching or escalating asthma medication at baseline 6. Change or escalation of the asthma medication to MF/IND/GLY in combination with the sensor system or another ICS+LABA+LAMA FDC according to the therapy decision of the treating physician 7. Availability of at least one ACT value of the last 6 months before consent 8. Cohort treated with MF/IND/GLY in combination with the sensor system * Owning an Android or iOS smartphone or tablet on which the app can be installed (via WiFi or mobile data network) and run (requires about 75 megabytes of storage space) and which is capable of establishing a Bluetooth connection to the sensor The patient must agree to activate the app, the Bluetooth connection and the mobile data connection regularly (at least once a month). * Availability of an e-mail address
Exclusion criteria
To participate in the study, none of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in asthma control test (ACT) score | Baseline, week 26 | ACT assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control. It is a self-administered questionnaire comprising five items that are assessed on a five point categorical scale (1 to 5) and the scores are summed to give a total score ranging from 5 to 25, with a score of \>=20 denoting 'controlled asthma', a score of 16-19 denoting 'partially controlled asthma', and a score of \<=15 denoting 'uncontrolled asthma'. The total score is calculated as the sum of the scores from all 5 questions. Higher scores indicates improved asthma control. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of of patient characteristics at baseline | Baseline | Description of patient characteristics at baseline in the treatment groups receiving MF/IND/GLY plus sensor or triple FDC will be provided |
| Percentage of patients showing an improvement in self-reported test adherence to inhalers (TAI) questionnaire | 26 weeks | TAI test is a 12-item questionnaire designed to assess the adherence to inhalers in patients with asthma. Ten questions are answered by the patients, and have to rate each question from 1 to 5. Total score can go between 10 and 50; 50 points correlates to adherent, 46-49 points correlates to moderate adherent and lower than 45 points correlate to not adherent. Two additional questions are answered by the physician |
| Course of adherence in the subgroup receiving MF/IND/GLY plus sensor | 26 weeks | Adherence course according to inhalation tracking data in the subgroup treated with MF/IND/GLY plus sensor will be provided |
| Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor | 26 weeks | Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor will be provided |
| Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician | Baseline | Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician will be provided |
| Percentage of patients with an ACT score <19 | 26 weeks | Percentage of patients with an ACT score of \<19 at baseline and following 26 weeks will be provided |
| Change in Post-dose trough Forced Expiratory Volume in one second (FEV1) | Baseline, week 26 | FEV 1 it is the amount that is exhaled in the first second of purposefully trying to breathe out as much air as possible. |
| Change in Forced vital capacity (FVC) | Baseline, week 26 | FVC is the volume of air that can forcibly be blown out after full inspiration, measured in liters. |
| Adverse events | 26 weeks | Adverse events will be provided |
| Percentage of patients achieving the minimal clinically important difference (MCID) change | Baseline, week 26 | Percentage of patients achieving the minimal clinically important difference (MCID) change from baseline ACT ≥ 3 points will be provided |
Countries
Germany
Outcome results
None listed